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1. Introduction 
Despite the increased use of living donors and marginal donor kidneys, there still exists a 
significant discrepancy between the organ supply and demand in renal transplantation [1]. 
This has led to excessive waiting times affecting patient survival. More than half of all 
patients with end-stage renal disease (ESRD) over the age of 60 die before receiving a kidney 
transplant [2]. These patients face a mortality rate of 6% per year while awaiting an 
acceptable donor. Thus, transplant surgeons and physicians have turned to other potential 
sources of allografts to meet the ever growing demand. Potential resources include 
maximizing the utilization of pediatric donors, increasing use of marginal donors, and 
transplanting hepatitis C (HCV) positive donor kidneys into HCV positive recipients. 
Finally, the advent of kidney paired donation has significantly improved and maximized 
the use of living donor renal transplants. 
The following chapter will discuss these sources of allografts and their associated outcomes. 
The goal of these donors is to maximize the potential opportunities for any patient on the 
deceased donor waiting list. Ultimately, these modalities will lead to improved patient 
survival and slightly offset the burden of the deceased donor waitlist. 
2. Pediatric donor 
2.1. Introduction 
The first attempt at using pediatric donors was in 1972 when en bloc kidneys were 
successfully transplanted in adult recipients [3]. By the late 1990’s, single pediatric donors 
were being successfully transplanted into adult recipients [4, 5]. This use of pediatric donors 
in adults has not disadvantaged the pediatric recipient population. In 2005, the United 
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Network for Organ Sharing (UNOS) mandated that pediatric recipients will be prioritized 
young adult deceased donor kidneys known as the Share-35 policy [6]. 
Pediatric kidneys can be transplanted as individual organs or en-bloc as dual kidneys. Some 
strongly advocated the use of single kidneys from pediatric donors, as opposed to en-bloc 
transplantation, to avoid the potential for technical complications [7]. Additionally, opponents 
of single pediatric donor kidney argue that the hyperfiltration syndrome associated with 
single kidneys leads to early graft failure in adult recipients [8, 9]. Pediatric donor size has 
been implicated as one of the important risks for graft failure. Initial studies demonstrated that 
technical complications, most notably graft thrombosis, was significantly higher in small 
pediatric donors (<10 kg) [9]. Moreover, as a result, pediatric donors represent the highest 
discard group with rates approaching 40% in donors less than 10 kg.  
In the following sections, we will discuss the advantages and disadvantages of the various 
types of pediatric donors. Short and long-term outcomes will be discussed with attention to 
perioperative outcomes associated with each. 
2.2. Small pediatric donor 
Several groups, including our own, have demonstrated the safety and feasibility of using 
young and small pediatric donors. Initial concerns regarding the use of these donors were 
related to both technical complications and allograft function. Given the high discard rate in 
this group, a discussion of their proper utilization and outcomes is important. 
Small pediatric donors, defined as weighing <10 kg and ages 5 years or younger, have been 
successfully transplanted into adult recipients. Balachandran et al. described a successful 
series of 27 small pediatric donors transplanted into adult recipients weighing >60 kg [10]. 
All kidneys were transplanted as single kidneys both with and without aortic cuffs (Carrel 
patch, Figure 1), with an end-to-side anastomosis to the recipient external iliac vessels. The 
majority of patients underwent rabbit antithymocyte globulin (r-ATG) induction therapy. In 
this series, no patient experienced a vascular complication and only 2 kidneys had primary 
non-function (both from the same donor). Patient and graft survival in this cohort at 2 years 
were 100% and 92.5%, respectively, which was not significantly different to their 
comparison group of standard adult kidney recipients of adult deceased donor kidneys. 
Borboroglu et al. also described a successful series of 15 single pediatric donors less than 2 
years of age transplanted into adult recipients [11]. The 2 years graft survival rate was 93% 
with a vascular thrombosis rate of 6.7%. 
In a review of over 12,000 pediatric donors, Bresnahan et al. demonstrate inferior graft 
survival in recipients of these kidneys compared to standard adult donors [8]. Pediatric 
donors 5 years of age or younger had the worst 1 year graft survival (76.3% in en-bloc 
kidney recipients and 72.2% in single kidney recipient). In this series, pediatric donors had a 
graft thrombosis rate of 10% in donors 5 years of age or less, 6% in donors aged 6 to 11 
years, and 5% in donors aged 12-17 years. The rate of primary non-function was 5%. Others 
have also described the increased incidence of vascular complications in these young and 
small pediatric donors [12]. 
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Figure 1. A pediatric kidney is implanted into the external iliac artery with the use of a Carrel patch. 
The inferior outcome of small pediatric donors was partly explained in the past by 
hyperfiltration injury. Hyperfiltration injury describes the compensatory mechanisms in the 
pediatric kidney that increase the glomerular capillary pressure in response to the 
inadequate filtration ability of the small graft. This concept was used to explain why 
transplanting en-bloc pediatric donors lead to improved outcomes as more “renal mass” 
was transplanted [8, 9]. However, opponents of this approach cite that en-bloc 
transplantation is a technically more challenging procedure with a relatively high surgical 
complication rate as well as a graft thrombosis rate of >10% [10, 13].  
2.3. En-bloc vs. single kidney transplantation 
Initial transplants from pediatric donors consisted of en-bloc transplantation in the recipient 
(Figure 2). As previously stated, this was described in 1972, and was the primary method 
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used for several years [3]. Solitary pediatric renal allografts were then later performed in the 
1990’s. The initial concerns regarding the use of single pediatric donors were two-fold: 
technical complications and poor graft survival.  
 
Figure 2. En-bloc pediatric kidney transplant. The following figure depicts en-bloc transplantation of 
pediatric kidneys into an adult recipient. The anastomosis is performed to the external iliac artery. The 
donor aorta and inferior vena cava are anastomosed to the recipient vessels as shown. 
Technical concerns regarding the use of single pediatric donors were the major concerns 
initially. Bresnahan and colleagues found that recipients of en-bloc pediatric donor 
allografts were less likely to develop graft thrombosis compared to single pediatric donor 
allografts (OR 0.688, P<0.01) [8]. A series of 20 en-bloc pediatric donor allografts 
demonstrated no vascular complications [14]. Borboroglu et al. compared 15 single pediatric 
donors to 33 en-bloc pediatric donors [11]. Four recipients of en-bloc pediatric donors 
experienced arterial thrombosis, whereas only one recipient of a single pediatric donor 
developed arterial thrombosis. Moreover, three recipients of en-bloc pediatric donors 
experienced ureteral complications, whereas none occurred in the single pediatric donor 
group. In a series of 27 single pediatric donor allografts, no recipient developed vascular 
thrombosis postoperatively [10].  
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Inferior graft survival has also been implicated as a reason to avoid using single pediatric 
donors. The initial studies by Bresnahan et al. demonstrated poorer graft survival in 
recipients of single versus en-bloc pediatric donor allografts at 1 year (72.2% versus 76.3%, 
respectively [8]. Additionally, a study utilizing the Scientific Registry of Transplant Recipients 
(SRTR) data demonstrated that recipients of single pediatric donors had a 78% increased risk 
of graft loss compared to en-bloc donors [9]. Graft survival of en-bloc pediatric donor 
allografts was similar to standard deceased donors. However, a more recent analysis of the 
SRTR database demonstrated that single pediatric donors >35 kg had similar graft survival to 
SCD [15]. Moreover, graft survival of single pediatric donors 10-35 kg was similar to SCDs. A 
later study by Balachandran et al. demonstrated better outcomes than their initial studies. The 
2 years graft survival rate in single pediatric donor recipients had improved to 92.5% [10]. 
Similarly, Borboroglu et al. demonstrated similar graft survival between single versus en-bloc 
pediatric donor allografts [11]. Effectively, the use of single pediatric donors compared to en-
bloc pediatric donors has resulted in more cumulative graft years in recipients.  
3. Marginal donor kidneys 
3.1. Overview 
The lack of available kidneys for transplantation in ESRD has lead to an increase use of 
suboptimal donors. As a result, more institutions are using expanded criteria donors (ECD) 
and deceased after cardiac death donors (DCD), sometimes referred to as marginal donors, 
to lessen the shortage [16-19]. The increased utilization of these organs has expanded the 
donor pool by 30% [19]. Nevertheless, there has been a concomitant increase in the rate of 
delayed graft function (DGF) and even primary non-function in DCD grafts [16-18]. 
Utilization of these kidneys may contribute to the donor pool, although it is important to 
maximize the outcomes of these allografts. 
3.2. Hypothermic machine perfusion 
Towards the end of the twentieth century, static cold storage was introduced to preserve 
kidneys procured from deceased donors, which lead to a decreased incidence of DGF and 
improvements in survival of DCD allografts [20]. Hypothermic machine perfusion (HMP) is 
an alternative to static cold storage (Figure 3). Several reports have demonstrated 
improvements in immediate graft function with the use of HMP compared to static cold 
storage [21-24]. Additionally, HMP permits longer preservation times without significant 
consequences to the allograft. Current notions suggest that HMP prevents and/or 
ameliorates injury to the kidney suffered as a result of preagonal hemodynamic and 
metabolic perturbations to the donor [25, 26].  
Various studies have demonstrated that vascular flow and resistance data of hypothermic 
machine perfused organs had a decrease in ischemic injury to the allograft prior to 
implantation compared to static cold storage [27-29]. Additionally, biochemical markers of 
ischemic injury can be measured and used to assess and evaluate pretransplant ischemic 
organ damage. In a study by Moers et al, 306 deceased donor kidneys, including DCD 
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donors, undergoing HMP were evaluated for relative concentrations of biomarkers 
associated with renal and tubular injury [30]. In this study, elevated levels of total 
glutathione-S-transferase (GST), N-acetyl-β-D-glucosaminidase (NAG), and heart-type fatty 
acid bind protein (H-FABP) were independent predictors of DGF. Thus, perhaps the 
phenomenon observed is an increase in ischemic injury to the kidney. The benefits of HMP 
may be somewhat negated if the allograft is removed prematurely and placed in static cold 
storage. 
 
Figure 3. LifePort® Kidney Transporter. The figure depicts the LifePort ® Kidney Transporter that 
gently pumps the kidney with cold storage solution which can increase the cold ischemia duration 
compared to static cold storage and potentially improve allograft outcomes in marginal donor kidneys. 
3.3. Allograft outcomes 
ECD allografts have decreased graft survival rates in comparison to SCD. In general, these 
kidneys have a life expectancy of 6 to 8 years, whereas standard or ideal kidneys last about 
10 to 12 years [31]. Prolonging allograft survival by preventing or minimizing mitigating 
factors for the development of DGF is imperative since DGF is a known risk factor for 
decreased allograft survival. Marginal donors are known to have a higher incidence of DGF, 
which could affect survival. 
Several studies have examined the incidence and effects of DGF in marginal donor kidneys. 
A study by Serur et al evaluated deceased donors over more than a 40 years period and 
demonstrated that the most significant risk factors for short-term graft survival were DGF 
and acute rejection, not just the mere utilization of ECD allografts [32]. A large prospective, 
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international, randomized controlled trial examined the efficacy of rATG versus basiliximab 
in patients at high risk of DGF [33]. Patients were maintained on a cyclosporine-based triple 
drug immunosuppression regimen and eligibility criteria included ECD or DCD allografts, 
SCD allografts with greater than 24 hours of cold ischemia time (CIT), repeat transplants, 
panel-reactive antibody value exceeding 20% before transplantation, donors with acute 
tubular necrosis (ATN), recipient black race, or one or more HLA mismatches. The incidence 
of DGF was not significantly different between patients receiving rATG and basiliximab. 
However, the incidence of biopsy-proven acute rejection was significantly lower in patients 
receiving rATG. Additionally, severe rejection episodes requiring antibody therapy were 
less frequent in the rATG group. 
Marginal donors were initially shown to have worse outcomes than SCD. Several earlier 
studies demonstrated worse graft survival in kidneys from ECDs [34, 35]. More recent data, 
however, suggests that ECD kidneys have similar short and intermediate survival as SCD 
kidneys; instead, allograft function is slightly worse in the ECD group [31]. This finding is 
not the general consensus as the more recent trend is to match the donor age to the recipient 
age to optimize outcomes. For example, Chavalitdhamrong et al. demonstrated that 
recipients over the age of 60 years receiving ECDs from donors over the age of 70 had better 
survival than recipients aged 41 to 60 years [36]. 
Numerous studies have also demonstrated an advantage and decreased risk of DGF in 
marginal donors preserved by HMP compared to static cold storage [37, 38]. However, other 
factors, such as race, have also been implicated as risk factors for DGF. Several studies have 
demonstrated that African-American recipients were more likely to develop DGF [39, 40]. 
Hariharan and colleagues observed lower rates of graft failure in Hispanic recipients and 
higher graft failure rates in kidneys from Hispanic donors (compared to white) [41]. 
4. Hepatitis C virus & transplantation 
4.1. Introduction 
Hepatitis C Virus (HCV) infection is a common condition among ESRD patients and kidney 
transplant recipients with infection rates between 11% and 49% [42-46]. The best screening 
test for HCV is nucleic acid testing, or NAT. Because organ transplantation can transmit the 
hepatitis C virus, the consensus remains that HCV positive donors should only be 
transplanted into HCV positive recipients [47, 48]. Initial studies suggested that patients with 
HCV infection have an increased risk of death following kidney transplantation [42, 44, 45]. 
More recent studies have demonstrated that HCV positive patients who receive a kidney 
transplant have superior survival than their counterparts who remain on hemodialysis [49, 50]. 
Thus, kidney transplantation remains the treatment of choice for HCV positive patients with 
ESRD and preserved liver function without any evidence of cirrhosis. 
4.2. Benefits of transplantation 
The use of HCV positive donors may have potential benefits to the respective HCV positive 
recipients. First, HCV positive recipients transplanted with a HCV positive donor have 
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waiting times that are almost 1 year less than their counterparts who wait for a HCV 
negative donor [51]. Nevertheless, HCV positive donor kidneys were about 2.6 times more 
likely to be discarded than HCV negative donors. HCV positive donors could receive high 
quality organs, especially when the donor is young. As previously discussed, there is a clear 
survival benefit to transplanting HCV positive recipients with HCV positive donors 
compared to remaining on the deceased donor waiting list. The use of hypothermic machine 
perfusion has been shown to decrease the viral load of the allograft prior to implantation 
[52]. The reported reduction in viral load in the kidney is anywhere from 75% up to 99% if 
the allograft was perfused for 20 hours and additional flushes were used. Finally, there may 
be a cost-benefit analysis to using HCV positive donors [53].  
4.3. Special transplant considerations 
The use of HCV positive donors is not without potential risks. First and foremost, 
superinfection with a different genotype of HCV could occur with transplantation [54]. This 
coupled with immunosuppression can lead to a more aggressive HCV infection and 
increased risk of developing active liver disease [55, 56]. Secondly, recent data suggests that 
the HCV positive recipient transplanted with an HCV positive donor generally experiences 
an increase in infectious complications [57]. Moreover, Rao and Ma demonstrated that the 
HCV positive recipient experienced not only more infectious complications, but also more 
serious life-threatening infections [56]. The use of induction therapy does not correlate with 
the level of viremia and has been shown to be safe and efficacious without increasing the 
risk of infections complications [58, 59]. Finally, HCV positive recipients with ESRD have a 
higher cardiovascular mortality [60].  
4.4. Outcomes following transplantation 
The short-term outcomes following transplantation of HCV positive donors into HCV 
positive recipients have generally been acceptable. Short-term patient survival rates at 1 and 
3 years have been reported to be as high as 93% and 83%, respectively, while graft survival 
rates were 91% and 77%, respectively [51]. The longest study of this cohort of patients comes 
from Spain with a 10 years total follow-up [61]. Patients had 5- and 10-year survival rates of 
about 85% and 73%, respectively. The death-censored 5- and 10-year graft survival rates 
were 69% and 47%, respectively. Graft survival, however, was significantly lower in HCV 
positive recipients receiving HCV positive donors. The use of a HCV positive donor was not 
a risk factor for mortality, graft loss or advanced liver disease in this study. Mahmoud and 
colleagues demonstrated an increased incidence of transplant glomerulopathy among HCV 
positive renal transplant recipients [62]. 
5. Kidney paired donation 
5.1. Introduction 
Up to one-third of all kidney transplant candidates presenting for living donor renal 
transplantation with a potential living donor will have a blood type or cytotoxic-dependent 
 
Expanding Opportunities for Kidney Transplantation 309 
cytotoxicity (CDC) crossmatch incompatibility [63]. In the past, these patients would be 
deemed unsuitable pairs and transplantation would not proceed. Some transplant centers 
may attempt to use desensitization protocols to overcome the immunologic incompatibility; 
however, these protocols carry the risk of additional immunosuppression. This added risk 
does not guarantee successful transplantation and, if successfully transplanted, places the 
recipient at an increased risk of an acute rejection episode [64, 65]. 
Kidney paired donation (KPD) was introduced as an effective tool to overcome 
immunologic barriers, such as blood type or CDC crossmatch incompatibility among 
donor/recipient pairs [66-68]. This initially began as a concept of swapping living donors in 
individual transplant centers with two or three paired donor exchanges to permit 
transplantation [69]. This has expanded to various nationwide registries of incompatible 
donor/recipient pairs of major transplant centers, including our own in the National Kidney 
Registry [66]. 
5.2. Living donor chains 
An important element of maximizing the benefits of KPD is the addition of an altruistic, or 
non-directed, donor. These donors wish to donate their kidney, however they do not have 
an intended recipient. Utilizing these altruistic donors in KPD registries permits the creation 
of transplant chains with an extra donor to spare. This extra donor is called a bridge donor 
and is able to donate at a later time (Figure 4). This potentially can create non-simultaneous 
extended altruistic donor (NEAD), or in other cases the bridge donor can even donate to the 
deceased donor waitlist [70]. 
Many different registries exist in the United States and these registries have facilitated the 
majority of KPD transplants performed to date. One of the important practical lessons 
learned over time is that it may be more beneficial to have bridge donors donate to a 
candidate on the deceased donor waiting list [66]. Sometimes it may take longer than expected 
to find a suitable recipient entered into a registry to match with a bridge donor. The bridge 
donor’s circumstances could change while awaiting donation, such as work or professional 
changes, economic inability to donate or the donor might renege on their decision to donate. 
Ultimately this would result in loss of the bridge donor and any future transplant generated by 
the bridge donor. The exception to this rule is blood type ‘O’ bridge donors who may be kept 
within the registry due to their ability to generate future transplant chains [71]. 
In order for chains to be successful, many logistical aspects need to be addressed. For 
example, only major transplant centers with operating room availability 24 hours a day 
should participate, as acute changes can occur regarding scheduling and require flexibility 
on the donor and recipient hospitals parts. Transplant coordinators with sound 
understanding of the KPD process are necessary to manage the complex logistical problems 
that may arise, and to manage entry of donors and recipients into the registry, obtain match 
offers, and participate in conference calls to coordinate and facilitate continuation of 
chains[66]. Transplant coordinators need to have GPS access to track organs shipped from 
other transplant centers. 
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Figure 4. Bridge Donor. The following figure depicts a chain of incompatible donor/recipients who are 
a part of a chain, beginning with an altruistic donor and ending with a bridge donor who may facilitate 
another chain. 
5.3. Benefits of kidney paired donation 
Kidney paired donation offers multiple benefits. First, transplant candidates are removed 
from the UNOS waiting list. These patients avoid the morbidity and mortality of initiating 
or remaining on hemodialysis as well as enjoying a survival benefit (U.S. Renal Data 
System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage 
Renal Disease in the United States, National Institutes of Health, National Institute of 
Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010). These patients benefit 
from receiving a living donor renal transplant, which has better graft survival than a 
deceased donor allograft. Moreover, these patients, who may undergo various 
desensitization protocols, avoid the added immunosuppression and risks involved in blood 
group incompatible transplants. These highly sensitized patients benefit from receiving a 
living unrelated transplant via a bridge donor. Furthermore, those candidates without a 
living donor would benefit from having additional patients removed from the deceased 
donor waiting list. 
In general, allografts from living donors have better outcomes than allografts from deceased 
donors. First, graft half-life is significantly longer in living donor allografts than deceased 
donors [72]. Second, the incidence of DGF is significantly lower in living donors, thus 
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recipients are receiving a better quality allograft. Even if allografts are shipped across the 
country with cold ischemia times that may exceed 12 hours, outcomes remain superior to 
deceased donors [68]. The benefits of higher quality organs could translate into 
improvements in quality of life for the recipient [73]. KPD maximizes opportunities for 
transplantation for all transplant candidates. 
6. Summary 
The supply of available allografts for kidney transplantation does not meet the demands of 
the growing number of patients listed for transplantation. Thus, other sources of available 
allograft must be sought to alleviate the burden of the deceased donor waiting list. The use 
of pediatric donors, en-bloc, or even better as single organs that can be split for two 
recipients represents a potential source of allografts. Marginal donors are also being 
increasingly used with respectable graft survival rates. The use of HCV positive donors for 
HCV positive recipients leads to the transplantation of HCV positive patients significantly 
faster than waiting for an HCV negative donor, which lessens the burden of those awaiting 
HCV negative organs. Finally, successful implementation of KPD transplant registries has 
lead to the transplantation of high quality organs with considerable graft life into patients 
with blood type incompatible or crossmatch positive donors. Finding a solution to the 
shortage of suitable organs remains a challenge that must continue to be addressed in the 
field of transplantation. 
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